Anti-Anaplastic Thyroid Cancer (ATC) Effects and Mechanisms of PLX3397 (Pexidartinib), a Multi-Targeted Tyrosine Kinase Inhibitor (TKI)

Anti-Anaplastic Thyroid Cancer (ATC) Effects and Mechanisms of PLX3397 (Pexidartinib), a Multi-Targeted Tyrosine Kinase Inhibitor (TKI)

Background Anaplastic thyroid cancer (ATC) is the greatest lethal thyroid neoplasm with a low incidence and lacks an effective treatment strategy and standardized treatment protocol. PLX3397 (Pexidartinib) is an FDA-approved multitarget tyrosine kinase inhibitor. The research is designed to explore...

Full description

Bibliographic Details
Main Authors: Jingtao Luo, Yun Wang, Lingkun Zhao, Chunli Wang, Ze Zhang
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Cancers
Subjects:
PLX3397 (Pexidartinib)
anaplastic thyroid cancer (ATC)
reactive oxygen species (ROS)
endoplasmic reticulum (ER) stress
Nrf2
Online Access:https://www.mdpi.com/2072-6694/15/1/172

Internet

https://www.mdpi.com/2072-6694/15/1/172

Similar Items